Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents
NCT00140842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47
Last updated 2021-11-02
Summary
This study will examine hormonal differences in ghrelin and growth hormone in obese and normal weight adolescents and their relationship to body composition and insulin resistance. The study will also investigate the effect of the macronutrient composition of a meal on postprandial ghrelin levels and whether ghrelin responses will predict the degree of hunger and caloric intake at a subsequent meal.
Conditions
Sponsors & Collaborators
-
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
Madhusmita Misra, MD · Massachusetts General Hospital
Eligibility
- Min Age
- 12 Years
- Max Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-05-31
- Primary Completion
- 2007-06-30
- Completion
- 2007-06-30
Countries
- United States
Study Locations
More Related Trials
-
Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
NCT00182091 ·Status: COMPLETED ·Phase: NA
-
Mechanism of Growth Hormone Effects on Adipose Tissue
NCT00453557 ·Status: COMPLETED ·Phase: PHASE4
-
Adipose Tissue and Serum Inflammation in GH Deficiency
NCT03500913 ·Status: COMPLETED
-
Growth Hormone Treatment of Young Growth Hormone-Deficient Adults
NCT00187993 ·Status: UNKNOWN
-
Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
NCT00720122 ·Status: COMPLETED ·Phase: PHASE2
-
Acylated Ghrelin Response to Acute Exercise in Obesity
NCT00486161 ·Status: COMPLETED
-
304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency
NCT00362063 ·Status: UNKNOWN ·Phase: NA
-
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
NCT00915954 ·Status: COMPLETED ·Phase: NA
-
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
NCT00004332 ·Status: COMPLETED
-
Growth Hormone and Glucose Metabolism
NCT00929799 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of GH and Lirglutide on AgRP
NCT05681299 ·Status: RECRUITING ·Phase: PHASE4
-
Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients
NCT00139945 ·Status: COMPLETED ·Phase: NA
-
Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.
NCT00720616 ·Status: WITHDRAWN ·Phase: NA
-
Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity
NCT00562796 ·Status: COMPLETED
-
Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly
NCT02115906 ·Status: UNKNOWN
-
The Association of Hormones and Peptides With Nutritional Consequences in Children With Feeding Difficulty.
NCT03045978 ·Status: COMPLETED
-
Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?
NCT02152124 ·Status: COMPLETED
-
The Effects of Growth Hormone (GH) on Lipid Depots
NCT00491582 ·Status: COMPLETED ·Phase: NA
-
Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)
NCT01020955 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
NCT01169103 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States
NCT00461240 ·Status: COMPLETED
-
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
NCT06326853 ·Status: NOT_YET_RECRUITING
-
Lipolytic Effects of GH in Human Subjects in Vivo
NCT02782221 ·Status: COMPLETED ·Phase: NA
-
Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight
NCT00120497 ·Status: UNKNOWN
-
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
NCT00163189 ·Status: COMPLETED ·Phase: PHASE3